Abstract:Targeting proteins' enzymatic functions with small molecule inhibitors, as well as functions of receptor proteins with small-molecule agonists and antagonists, were the major forms of small-molecule drug development. These small-molecule modulators are based on a conventional occupancy-driven pharmacological approach. For proteome space traditionally considered undruggable by small-molecule modulators, such as enzymes with scaffolding functions, transcription factors, and proteins that lack well-defined binding pockets for small molecules, targeted protein degraders offer the opportunity to drug the proteome with an event-driven pharmacological approach. A degrader molecule, either PROTAC or molecular glue, brings the protein of interest (POI) and E3 ubiquitin ligase in close proximity and engages the ubiquitin-proteasome system (UPS), the cellular waste disposal system for the degradation of the POI. For the development of targeted protein degraders to meet therapeutic needs, several aspects will be considered, namely, the selective degradation of disease-causing proteins, the oral bioavailability of degraders beyond Lipinski's rule of five (bRo5) scope, demands of new E3 ubiquitin ligases and molecular glue degraders, and drug resistance of the new drug modality. This review will illustrate several under-discussed key considerations in targeted protein degradation drug discovery and development: 1) the contributing factors for the selectivity of PROTAC molecules and the design of PROTACs to selectively degrade synergistic pathological proteins; 2) assay development in combination with a multi-omics approach for the identification of new E3 ligases and their corresponding ligands, as well as molecular glue degraders; 3) a molecular design to improve the oral bioavailability of bRo5 PROTACs, and 4) drug resistance of degraders.

Investigating Protein Degradability through Site-Specific Ubiquitin Ligase Recruitment

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Discovery of E3 Ligase Ligands for Target Protein Degradation

Bivalent Ligands for Protein Degradation in Drug Discovery

Targeted protein degradation: expanding the toolbox

Protein degradation by small tag artificial bacterial E3 ligase

Targeted Degradation of 53BP1 Using Ubiquitin Variant Induced Proximity

Leveraging dual-ligase recruitment to enhance degradation via a heterotrivalent PROTAC

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

Exploiting the Cullin E3 Ligase Adaptor Protein SKP1 for Targeted Protein Degradation

Proteome-scale discovery of protein degradation and stabilization effectors

Key Considerations in Targeted Protein Degradation Drug Discovery and Development

Identification of KLHDC2 as an efficient proximity-induced degrader of K-RAS, STK33, β-catenin, and FoxP3

Targeted protein degradation via intramolecular bivalent glues

PROTAC-induced Protein Structural Dynamics in Targeted Protein Degradation

Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes

Principles of paralog-specific targeted protein degradation engaging the C-degron E3 KLHDC2

Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications

Leveraging Dual-Ligase Recruitment to Enhance Protein Degradation via a Heterotrivalent Proteolysis Targeting Chimera

Targeted Kinase Degradation via the KLHDC2 Ubiquitin E3 Ligase

A Tale of Two Tails: Efficient Profiling of Protein Degraders by Specific Functional and Target Engagement Readouts